Cited by 33Computational Drug Discovery MethodsCell Image Analysis TechniquesCOVID-19 diagnosis using AI

Deep Learning for Drug Discovery: A Study of Identifying High Efficacy Drug Compounds Using a Cascade Transfer Learning Approach

Open access
Zhuang, Dylan, Ibrahim, Ali K.·2021·Applied Sciences

Abstract

In this research, we applied deep learning to rank the effectiveness of candidate drug compounds in combating viral cells, in particular, SARS-Cov-2 viral cells. For this purpose, two different datasets from Recursion Pharmaceuticals, a siRNA image dataset (RxRx1), which were used to build and calibrate our model for feature extraction, and a SARS-CoV-2 dataset (RxRx19a) was used to train our model for ranking efficacy of candidate drug compounds. The SARS-CoV-2 dataset contained healthy, uninfected control or “mock” cells, as well as “active viral” cells (cells infected with COVID-19), which were the two cell types used to train our deep learning model. In addition, it contains viral cells treated with different drug compounds, which were the cells not used to train but test our model. We devised a new cascade transfer learning strategy to construct our model. We first trained a deep learning model, the DenseNet, with the siRNA set, a dataset with characteristics similar to the SARS-CoV-2 dataset, for feature extraction. We then added additional layers, including a SoftMax layer as an output layer, and retrained the model with active viral cells and mock cells from the SARS-CoV-2 dataset. In the test phase, the SoftMax layer outputs probability (equivalently, efficacy) scores which allows us to rank candidate compounds, and to study the performance of each candidate compound statistically. With this approach, we identified several compounds with high efficacy scores which are promising for the therapeutic treatment of COVID-19. The compounds showing the most promise were GS-441524 and then Remdesivir, which overlapped with these reported in the literature and with these drugs that are approved by FDA, or going through clinical trials and preclinical trials. This study shows the potential of deep learning in its ability to identify promising compounds to aid rapid responses to future pandemic outbreaks.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/app11177772

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Deep learning has been successfully used to predict the efficacy of drug compounds with high accuracy.

    “The successful use of deep learning (DL) to predict the efficacy of drug compounds with high accuracy has been described recently by the authors of [5].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhuang, D., & Ibrahim, A. K.
Affiliations
Florida Atlantic University (US)
Corresponding author
Ibrahim, Ali K.
Venue
Applied Sciences
Publisher
MDPI AG
Published
2021-08-24
Volume
11
Issue
17
Pages
7772
ISSN
2076-3417 (ISSN-L)
OpenAlex
W3196174677
Cited by
33
References
27
Citations by year
2026: 3 · 2025: 10 · 2024: 10 · 2023: 4 · 2022: 5 · 2021: 1
FWCI
2.64
Type
journal article
Language
en
Open access
Locations
  • Applied Sciences (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biophysics › Cell Image Analysis Techniques
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › COVID-19 diagnosis using AI
Keywords
drug discovery, COVID-19 pandemic, SARS-CoV-2, DenseNet, GS-441524, remdesivir, feature extraction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review